Bio-Path Holdings, Inc. · OTC:BPTH
Bio-Path — Investor Presentation (May 2019)
23 slides from Bio-Path's investor presentation, May 2019

Slide 1: Bio-Path Holdings: An Oncology-Focused Biotechnology Company
Bio-Path Holdings An Oncology-Focused Biotechnology Company May 2019

Slide 2: Forward looking statements
Forward looking statements This Presentation contains forward-looking statements with respect to business conducted by Bio-Path Holdings, Inc. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will

Slide 3: Introducing Bio-Path Holdings
Introducing Bio-Path Holdings Advanced Oligonucleotide Therapeutics with High Efficiency Systemic Delivery Publicly traded Employees Established NASDAQ 13 Houston, TX BPTH 2007 Technology Highlights ® DNAbilize Technology, next generation single-stranded DNA antisense Robust clinical pipeline with n

Slide 4: Robust Oncology Pipeline
Robust Oncology Pipeline Preclinical IND PHASE I PHASE II Prexigebersen (BP1001) AML* Prexigebersen (BP1001) CML* Prexigebersen (BP1001) Solid Tumors (ovarian, endometrial, pancreatic) *Orphan drug designation from the USFDA for AML and CML and from EMA for AML BP1002 (Liposomal Bcl2) Lymphoma, CLL

Slide 5: DNAbilize Technology
DNAbilize Technology ® Proven As Safe, Robust and Targeted Method for Treating Disease No Toxicity No Toxicity With human patients to date in Prexigebersen clinical trial. • DNAbilize™ liposome structure is similar to the cellular membrane • P-ethoxy DNA does not induce hepatotoxicity or thrombocyto

Slide 6: DNAbilize Technology: Nanoparticle Delivery Ensures Stabilization
DNAbilize Technology ® Nanoparticle Delivery Ensures Stabilization • Lack of surface charge on lipid nanoparticle means avoidance of steric hindrance and ensures cellular uptake. • Slight hydrophobic nature allows the oligonucleotide Neutral liposome nanoparticle to incorporate readily into the lipi

Slide 7: DNAbilize Technology: Compared to other Antisense
DNAbilize Technology ® Compared to other Antisense 1st Generation 2nd Generation DNAbilize® No toxicity Systemic Delivery Target Specific Effectiveness High Cellular Uptake Neutral charged stabilizing DNA backbone Unlike other antisense technologies that demonstrate toxicities and poor cellular deli

Slide 8: DNAbilize Lead Target and Indications: Grb2 and Myeloid Leukemia
DNAbilize® Lead Target and Indications: Grb2 and Myeloid Leukemia Prexigebersen is an antisense RNAi nanoparticle targeting Grb2 • Ideal target for myeloid leukemia because it shuts down the Ras pathway in receptor activated myeloid cells without exerting adverse effects on Ras signaling through oth

Slide 9: Prexigebersen (BP1001): A Promising Treatment of Myeloid Leukemia
Prexigebersen (BP1001): A Promising Treatment of Myeloid Leukemia Prexigebersen in combination with LDAC was well-tolerated and showed early anti-leukemic activity in nearly 50% of evaluable AML patients in Stage 1 of our Phase 2 studies PK: 30 hour half life in plasma 1 No adverse effects attribute

Slide 10: Summary of Phase I Monotherapy Clinical Trial Results for Prexigebersen
Summary of Phase I Monotherapy Clinical Trial Results for Prexigebersen • N=39, AML, CML, & MDS Patients Refractory or Resistant to Current Therapies - Patients averaged 6 prior therapies • Dose escalating treatment cycle, 8 doses over 4 weeks, up to 90 mg/m2 • NO ADVERSE EVENTS/DRUG WAS WELL TOLERA

Slide 11: Phase I Conclusions
Phase I Conclusions Results support that Grb2 is a potential therapeutic target for haematological malignancies • Favorable safety profile strongly suggests that BP1001 has a very different toxicity profile than other antisense oligonucleotide analogues, which have been associated with serum transam

Slide 12: Stage 1 of the Phase II Efficacy Trial Design for AML
Stage 1 of the Phase II Efficacy Trial Design for AML Prexigebersen Combination Therapy • Treatment of de novo AML patients who are induction therapy ineligible and unfit for stem cell transplant • Efficacy trial conducted at 6 leading cancer centers in the U.S., including the MD Anderson Cancer Cen

Slide 13: Safety Segment Phase II Prexigebersen
Safety Segment Phase II Prexigebersen + LDAC Combination Therapy Show Encouraging Results Relapsed/refractory AML patients - 3 evaluable patients per cohort, 2 cohorts, n=6 - Dose 60 mg/m2 and 90 mg/m2 respectively - Received drug 2x week for 4 weeks per treatment cycle Excellent Results - 3 patient

Slide 14: Results of Stage 1 Interim Analysis
Results of Stage 1 Interim Analysis Patient evaluation summary 5 Patients achieved CR (30%) Note: LDAC alone CR rate 7-13% +65% 6 Patients achieved stable disease (35%) 17 2 Stable disease patients had >50% bone marrow blasts reductions Of the evaluable patients 65% 1 CR patient was eligible for and

Slide 15: Prexigebersen Phase 1b/2a CML Study
Prexigebersen Phase 1b/2a CML Study Potential to treat the 33% of CML patients who are Gleevec resistant • Phase 1b prexigebersen + dasatinib study Determine safety of the combination in accelerated and blast crisis CML patients 2 cohorts of 3 evaluable patients at 60 mg/m2 and 90 mg/m2 Compar

Slide 16: Prexigebersen-A Phase 1 Study in Solid Tumors
Prexigebersen-A Phase 1 Study in Solid Tumors • Prexigebersen efficacy against ovarian tumors enhanced when combined with paclitaxel • Prexigebersen in combination with gemcitabine efficacious against pancreatic tumors • Clinical Plans First - open a Phase 1/1b study of prexigebersen + paclitaxel

Slide 17: BP1002 is an antisense RNAi nanoparticle targeting Bcl-2
BP1002 is an antisense RNAi nanoparticle targeting Bcl-2 Bcl-2 antisense oligo Oncogenic stress Cytotoxic Chemotherapy stimuli Radiation Mitochondria Anti-apoptotic BH3-only Bax Bak proteins Bcl-2 protein Apoptotic Cytochrome c proteins Apaf 1 Apoptotic Effector cell death caspases Caspase 9 By bloc

Slide 18: BP1002 Summary
BP1002 Summary • BP1002 decreased viability of lymphoma cells (11 of 15 lymphoma cell lines) • BP1002 extended survival of mice bearing lymphoma xenografts • Completed IND-enabling studies (pharmacokinetics, rodent toxicology), expected IND 3Q19 • Launch Phase 1 in lymphoma and CLL at MD Anderson, o

Slide 19: BP1003 Targeting STAT3
BP1003 Targeting STAT3 • BP1003 has efficacy against non-small cell lung cancer, AML, and pancreatic cancer cells • BP1003 + gemcitabine combination is efficacious in pancreatic cancer-derived tumors • IND enabling studies during 2019 • Conduct a Phase 1 study of BP1003 in patients with refractory/m

Slide 20: Experienced Leadership Team
Experienced Leadership Team Officer and Director Medical consultant for Medimmune, Peter Nielsen since founding William Hahne, M.D. Lion Biotechnologies, Seattle Co-Founder, President, Company in 2007 Genetics, Aminex Therapeutics, Vice President of Chief Executive Officer Therakos, and Celgene Cell

Slide 21: Scientific Advisory Board
Scientific Advisory Board Jorge Cortes, M.D. • M.D. from la Facultad de Medicina, Universidad Nacional Autónoma de México • Jane and John Justin Distinguished Chair in Leukemia Research, Chief of the AML and CML sections, and Chairman Deputy Chair of the Department of Leukemia at The University of T

Slide 22: IP and Financial Snapshot
IP and Financial Snapshot Intellectual Property • Original patents licensed from MD Anderson • New composition and methods of use patent issued covers DNAbilize® technology, solely owned by Bio-Path • Five additional patents pending Financial Snapshot • Ticker: NASDAQ: BPTH • Cash: $19.3 million as

Slide 23: Bio-Path Holdings: Thank you
Bio-Path Holdings Thank you Bio-Path Holdings, Inc. 4710 Bellaire Blvd Suite 210 Bellaire, TX 77401 Web: www.biopathholdings.com Mail: partnering@biopathholdings.com Tel: (832) 742-1369 23
Source: Internet Archive copy of biopathholdings.com
More decks from Bio-Path Holdings, Inc.
Investor Presentation (May 2022)12 slides · May 2022
Investor Presentation (January 2022)17 slides · January 2022
Investor Presentation (March 2021)17 slides · March 2021
Shareholder Meeting (December 2020)16 slides · Dec 21, 2020
Investor Presentation (October 2017)20 slides · October 2017
Investor Presentation (July 2017)22 slides · July 2017